MedPath

Efficacy and Safety Study of Intra-Articular Injections of Autologous Peripheral Blood Stem Cells Following Subchondral Drilling Surgery for the Treatment of Articular Cartilage Injury in the Knee

Phase 2
Completed
Conditions
Articular Cartilage Disorder of Knee
Articular Cartilage; Degeneration
Registration Number
NCT03101163
Lead Sponsor
KLSMC Stem Cells, Inc.
Brief Summary

This is a 24-month, multicenter, randomized, open-label, standard treatment-controlled, parallel-group, Phase 2 study for adults with large or complicated knee articular cartilage lesions and are candidates for knee joint cartilage repair surgery. The safety and efficacy of intra-articular injections of peripheral blood stem cells (PBSCs) together with hyaluronic acid (HA) after subchondral drilling surgery will be evaluated to determine whether PBSC therapy can improve functional outcome and reduce pain of the knee joint better than a standard treatment (HA injections and physiotherapy regimen).

Detailed Description

This is a 24-month, multicenter, randomized, open-label, standard treatment-controlled, parallel-group, Phase 2 study for adults with large or complicated knee articular cartilage lesions and are candidates for knee joint cartilage repair surgery. The safety and efficacy of intra-articular injections of peripheral blood stem cells (PBSCs) together with hyaluronic acid (HA) after subchondral drilling surgery will be evaluated to determine whether PBSC therapy can improve functional outcome and reduce pain of the knee joint better than a standard treatment (HA injections and physiotherapy regimen).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
120
Inclusion Criteria
  • Aged between 18 to 55 years at screening (20 to 57 years for the open-label extension)

  • Present for evaluation and treatment of knee pain, knee swelling, or knee mechanical symptoms due to cartilage lesions

  • Provide written informed consent

  • International Cartilage Repair Society (ICRS) Grade 3 or 4 lesions diagnosis from MRI scans of the target knee

  • All subjects must also satisfy at least 1 of the following inclusion criteria:

    • Isolated knee articular cartilage lesion (single lesion) estimated to be ≥3 cm2 as demonstrated on MRI scanning. Multiple knee articular cartilage lesions (multiple lesions) with at least 1 lesion estimated to be ≥3 cm2 as demonstrated on MRI scanning. Bipolar cartilage defects demonstrated on MRI scanning with at least 1 articular surface lesion to be ≥3 cm2. One or more cartilage defects involving the patello-femoral joint as demonstrated on MRI scanning with at least 1 lesion ≥3 cm2. One or more cartilage defects involving the tibio-femoral joint as demonstrated on MRI scanning with at least 1 lesion to be ≥3 cm2. Previously failed cartilage repair procedures (i.e., microfracture, osteochondral autograft transplantation surgery (OATS), ACI)
Exclusion Criteria
  • Three or more previous surgical interventions on the knee in question.
  • Preoperative flexion deformity greater than 10 degrees.
  • Presence of ligamentous injury which would require reconstruction, varus or valgus deformity requiring osteotomy, or cases that require complex surgery prior to cartilage regeneration

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Knee injury and Osteoarthritis Outcome (KOOS) pain subdomain24 months

KOOS pain subdomain score as a measure of joint pain

International Knee Documentation Committee (IKDC) score24 months

Subjective IKDC core as a measure of joint function

Secondary Outcome Measures
NameTimeMethod
Numeric Rating Scale (NRS) for pain24 months

Numeric Rating Scale (NRS) for pain

Trial Locations

Locations (2)

Andrews Research & Education Foundation (AREF)

🇺🇸

Gulf Breeze, Florida, United States

Kuala Lumpur Sports Medicine Centre

🇲🇾

Kuala Lumpur, Malaysia

Andrews Research & Education Foundation (AREF)
🇺🇸Gulf Breeze, Florida, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.